<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966261</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A01632-53</org_study_id>
    <nct_id>NCT03966261</nct_id>
  </id_info>
  <brief_title>The Role of Incretins in Bone Remodeling in Humans</brief_title>
  <acronym>INCREMOS</acronym>
  <official_title>INcrétines et REModelage OSseux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of incretins (GIP and GLP-1) on cells and bone tissue has been shown in cellular and&#xD;
      animal studies. In humans, the role of these hormones is mainly studied in the&#xD;
      pathophysiology of diabetes, their effect on bone is unknown. The serum incretin&#xD;
      concentration is low and increases rapidly after a meal. This increase is brief, incretins&#xD;
      being rapidly degraded by dipeptidylpeptidase 4 (DPP-4). The dosage of these hormones is&#xD;
      complex and the basal &quot;normal&quot; serum concentrations and after feeding in healthy subjects are&#xD;
      unknown. Before any study on the effect of incretins on bone remodeling in humans, it is&#xD;
      necessary to establish physiological concentrations of incretins in healthy subjects.&#xD;
&#xD;
      The aim of this study is to estimate physiological concentrations of incretins in healthy&#xD;
      subject.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incretins concentrations before and after a meal in healthy subjects</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Incretins</condition>
  <condition>Osteoporosis</condition>
  <condition>Bone Remodeling</condition>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>we perform blood sample in healthy subject before and after a meal to measure incretins concentration</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy women and men aged from 30 to 70 years without bone patholog nor pathological&#xD;
        condition influencing bone remodeling nor treatment influencing bone remodeling&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy women and men&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known osteoporosis&#xD;
&#xD;
          -  osteoporotic fracture&#xD;
&#xD;
          -  tobacco&#xD;
&#xD;
          -  alcohol : &gt; 2 glasses/day&#xD;
&#xD;
          -  type 1 and type 2 diabetes&#xD;
&#xD;
          -  BMI &lt; 19kg/m² or &gt; 30kg/m²&#xD;
&#xD;
          -  heart failure, kidney failure&#xD;
&#xD;
          -  cancer&#xD;
&#xD;
          -  bariatric surgery&#xD;
&#xD;
          -  graft&#xD;
&#xD;
          -  cirrhosis&#xD;
&#xD;
          -  use in the past year : bisphosphonate, denosumab, raloxifene, teriparatide, oral or IV&#xD;
             glucocorticoid during 3 months or more&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benoit GOBRON, Dr</last_name>
    <phone>+33241353576</phone>
    <email>Benoit.Gobron@chu-angers.fr</email>
  </overall_contact>
  <reference>
    <citation>Mabilleau G. Interplay between bone and incretin hormones: A review. Morphologie. 2017 Mar;101(332):9-18. doi: 10.1016/j.morpho.2016.06.004. Epub 2016 Aug 8. Review.</citation>
    <PMID>27423214</PMID>
  </reference>
  <reference>
    <citation>Mabilleau G, Gobron B, Mieczkowska A, Perrot R, Chappard D. Efficacy of targeting bone-specific GIP receptor in ovariectomy-induced bone loss. J Endocrinol. 2018 Aug 18. pii: JOE-18-0214. doi: 10.1530/JOE-18-0214. [Epub ahead of print]</citation>
    <PMID>30121578</PMID>
  </reference>
  <reference>
    <citation>Mabilleau G, Gobron B, Bouvard B, Chappard D. Incretin-based therapy for the treatment of bone fragility in diabetes mellitus. Peptides. 2018 Feb;100:108-113. doi: 10.1016/j.peptides.2017.12.008. Review.</citation>
    <PMID>29412811</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

